medigraphic.com

2016, Number S1

<< Back Next >>

Rev Mex Anest 2016; 39 (S1)

Sugammadex: myths and realities

Mille-Loera JE, González-Chon O

Language: Spanish
References: 11
Page: 82-85
PDF size: 205.77 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Claudius C, Garvey LH, Viby-Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia. 2009;64:10-21.

  2. Martyn JAJ, Fagerlund MJ, Eriksson. Basic principles of neuromuscular transmission. Anaesthesia. 2009;64:1-9.

  3. Karwacki Z, Niewiadomski S, Rzaska M. The use of sugammadex for the reversal of vecuronium-induced neuromuscular block following intracranial surgery. Anaesthesiol Intensive Ther. 2015;47:297-302.

  4. Kobielska S. Sugammadex-indications and clinical use. Anaesthesiol Intensive Ther. 2013;45:106-110.

  5. Nag K, Roshan DS, Shetti AN, Kumar H, Sivashanmugam T, Pathasarathy S. Sugammadex: a revolutionary drug in neuromuscular pharmacology. Anesth Essays and Researches. 2013;7:302-306.

  6. Lee C, Jahr JS, Candiotti KA, Warriner B. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009;110:1020-1025.

  7. Fernández MLA, Álvarez BM. Sugammadex: nuevo fármaco reversor del bloqueo neuromuscular. Rev Esp Anestesiol Reanim. 2010;57:95-102.

  8. Ledowsky T, Hillyard S, O’Dea B, Archer R, Vilas BF, Kyle B. Introduction of sugammadex as standard reversal agent: impact on the incidence of residual neuromuscular blockade and postoperative patients outcome. Indian J Anaesth. 2013;57:46-51.

  9. García del Busto-Enguer N. Sugammadex (DCI): publicación de la Dirección General de Farmacia y Productos Sanitarios. Generalitat, Consellería de Sanitat. Valencia, España. 2010; 47:1-7. Disponible en: http://www.san.gva.es/cas/prof/dgf/homedgf.htlm

  10. Paton F, Paulden M, Chambers D. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010;105:558-567.

  11. — Ficha técnica Sugammadex. European Public Assessment Report. Disponible en: http://www.ema.europa.eu Agencia Europea de Medicamentos




2020     |     www.medigraphic.com